A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma-Reference-Cited by-同舟云学术

A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma

Published:2013-02-28 Issue:6 Volume:108 Page:1252-1259
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Meyer T,Kirkwood A,Roughton M,Beare S,Tsochatzis E,Yu D,Davies N,Williams E,Pereira S P,Hochhauser D,Mayer A,Gillmore R,O'Beirne J,Patch D,Burroughs A K

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201385.pdf

Reference34 articles.

1. Asghar U, Meyer T (2012) Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol 56 (3): 686–695

2. Brown KT, Gonen M, Gian Do K, Covey AM, Getrajdman GI, Zhao B, Sofocleous CT, Beattie C, DeMatteo RP, Solomon SB, Abou-Alfa GK (2012) A randomized single blind controlled trial of beads versus doxorubicin-eluting beads for arterial embolization of hepatocellular carcinoma (HCC). J Clin Oncol 30 (suppl 34): abstract 143

3. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 (3): 421–430

4. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI, Bruix J (2012) Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 56 (6): 1330–1335

5. Burroughs A, Hochhauser D, Meyer T (2004) Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 5 (7): 409–418

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current research status of transarterial therapies for hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-09-15

2. Trans-Arterial Chemoembolization or Bland Embolization for the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis;2024-06-18

3. Transarterial embolization is an acceptable bridging therapy to hepatocellular carcinoma prior to liver transplantation;World Journal of Transplantation;2024-06-18

4. Embolization alone is as effective as TACE for unresectable HCC: systematic review and meta-analysis of randomized controlled trails;BMC Gastroenterology;2024-06-07

5. Outcomes of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma: A tertiary center experience;Pakistan Journal of Medical Sciences;2024-05-21